


COVID-19: Abnormal liver function tests

Graphical abstract



Authors

Qingxian Cai, Deliang Huang, Hong Yu, ..., Jun Chen, Lei Liu, Lin Xu

Correspondence

drchenjun@163.com (J. Chen), liulei3322@aliyun.com (L. Liu), xulin27@mail.sysu.edu.cn (L. Xu).

Lay summary

Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients.

Highlights

- Of 417 patients with COVID-19, 76.3% had abnormal liver tests and 21.5% had liver injury during hospitalization.
- Patients with abnormal liver tests had significantly higher odds of developing severe pneumonia.
- The use of lopinavir/ritonavir increased the odds of liver injury by 4-fold.

COVID-19: Abnormal liver function tests

Qingxian Cai^{1,*}, Deliang Huang^{1,#}, Hong Yu^{1,*}, Zhibin Zhu¹, Zhang Xia¹, Yinan Su¹, Zhiwei Li¹,
Guangde Zhou¹, Jizhou Gou¹, Jiuxin Qu¹, Yan Sun¹, Yingxia Liu¹, Qing He¹, Jun Chen^{1,*†},
Lei Liu^{1,*†}, Lin Xu^{2,*†}

¹National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, 518100, China; ²School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China

Background & Aims: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results.

Methods: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis.

Results: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3× the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19–6.3, and 4.44, 95% CI 1.93–10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both $p < 0.01$).

Conclusion: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on

liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently.

Lay summary: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients.

© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Coronaviruses are a family of viruses that are known to cause both respiratory and intestinal diseases in various animal species and humans.¹ These viruses tend to target the upper respiratory tract, causing anywhere from moderate to severe illnesses, such as the cold or in more extreme cases, pneumonia. To date, 7 human coronaviruses have been identified, including the 3 epidemic viruses of severe acute respiratory syndrome (SARS)-CoV, middle east respiratory syndrome (MERS)-CoV and the newest, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).² These 3 epidemic viruses have similar sequence identity, sharing more than 50% genome sequences.³ In December of 2019, a series of pneumonia cases of unknown origin began to spread in the central city of Wuhan, China. Now identified as SARS-CoV-2, the virus had gone on to infect more than 300,000 people worldwide by March 2020.⁴ The coronavirus disease (COVID-19) has been labelled a pandemic by the World Health Organization (WHO) having led to thousands of deaths and hospitalizations worldwide. While most COVID-19 cases have been identified as mild, more extreme diagnoses have led to respiratory failure, septic shock, and/or multiple organ dysfunction.⁵ As this infectious disease continues to spread, further clinical and epidemiological characteristics must be elucidated to improve our understanding of the true extent of the virus, in order to improve diagnostic and treatment capabilities and reduce its overall impact on morbidity and mortality.

Recently, there has been some insight into the impact of COVID-19 on other organs, as a number of reports have indicated that more than half of patients with COVID-19 showed varying

Keywords: 2019-nCoV; SARS-Cov-2; Pneumonia; Critical care; Liver injury; Liver tests; Bilirubin.

Received 17 March 2020; received in revised form 7 April 2020; accepted 7 April 2020; available online xxx

* Corresponding authors. Addresses: Department of Liver Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, 518100, China. Tel: (86) 755-61222333; Fax: (86) 755-61238928 (J. Chen), or National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, 518100, China. Tel: (86) 755-61222333; Fax: (86) 755-61238928 (L. Liu), or School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China. Tel: (86) 20-87335523; Fax: (86) 20-87330446 (L. Xu).

E-mail addresses: drchenjun@163.com (J. Chen), liulei3322@aliyun.com (L. Liu), xulin27@mail.sysu.edu.cn (L. Xu).

† These authors contributed equally to this manuscript.

These authors contributed equally to this manuscript.

<https://doi.org/10.1016/j.jhep.2020.04.006>



ELSEVIER

levels of liver disease.⁶ A new study found that the SARS-CoV-2 virus may bind to angiotensin-converting enzyme 2 (ACE2) on cholangiocytes, leading to cholangiocyte dysfunction and inducing a systemic inflammatory response leading to liver injury.⁷ As of March 10, 2020, 7 relatively large-scale hospital-based studies have reported the clinical characteristics of patients with COVID-19, including some insights into other factors, which may lead to COVID-19 induced liver damage.^{8–14} In these studies, elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported, ranging from 14% to 53%.^{8,9,11,14} Additionally, a pathological study of liver biopsy specimens from a patient who died from COVID-19 showed moderate microvesicular steatosis and mild lobular and portal activity, indicating that SARS-CoV-2 may have led to this liver damage.¹⁵ However, little data exists that has comprehensively analyzed other liver enzymes and clinical characteristics of liver failure among patients with COVID-19. Hence, the aim of this study was to report the clinical course and liver test parameters in patients with COVID-19 admitted to the only referral hospital in Shenzhen, China. With better knowledge of pathogenesis, more targeted therapies and holistic care models could be developed, which may help to prevent severe liver injury or failure in patients with COVID-19.

Patients and methods

Study design and participant criteria

This was a cross-sectional study among patients recruited from the Third People's Hospital of Shenzhen, which is the only referral hospital in Shenzhen, China. From January 11, 2020 to February 21, 2020, 417 patients diagnosed with COVID-19 based on the WHO interim guidance¹⁶ were identified. Those that had ≥ 1 abnormal liver test result from admission to the end of February 2020 were enrolled in the study. This study was approved by the Ethics Committee of The Third People's Hospital of Shenzhen (2020 019). All patients provided signed informed consent. It was not appropriate or possible to involve patients or the public in the design, conduct, or reporting of our research.

Confirmation of COVID-19

The presence of SARS-CoV-2 was detected by real-time reverse transcription PCR.¹⁷ Two pairs of primers targeting the open reading frame 1ab (ORF1ab) and the nucleocapsid protein (N) were amplified and examined. The corresponding sequences for ORF1ab were 5'-CCCTGTGGGTTTACACTTAA-3' (F), 5'-ACGA TTGTGCATCAGCTGA-3' (R), and 5'-CY3-CCGTCTGCGGTATGTGG AAAGGTTATGG-BHQ1-3' (probe), and those for N were 5'-GGGGAACCTCTCCTGCTAGAAT-3' (F), 5'-CAGACATTTGCTCTCA AGCTG-3' (R), and 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3' (probe). Each sample was run in triplicate with positive and negative control sets, as suggested. These diagnostic criteria were based on the recommendations by the National Centers for Disease Control and Prevention of China (China CDC). The Shenzhen CDC reconfirmed samples that were identified as positive for SARS-CoV-2 by the local laboratory.

Liver test parameters and abnormalities

Liver test abnormalities were defined as the elevation of the following liver enzymes in serum: ALT >40 U/L, AST >40 U/L, gamma-glutamyltransferase (GGT) >49 U/L, alkaline phosphatase (ALP) >135 U/L, and total bilirubin (TBIL) >17.1 $\mu\text{mol/L}$. As COVID-19 is a new, emerging infectious disease, guidance or consensus

on liver injury classifications are lacking. Thus, we classified the pattern of these abnormalities as hepatocellular, cholestatic, or mixed. Patients who had raised ALT and/or AST more than $3\times$ the upper limit unit of normal (ULN) were classified as hepatocyte type; patients who had raised ALP or GGT twice the ULN were classified as cholangiocyte type; and patients who had a combination of both ALT/AST elevated more than $3\times$ the ULN and ALP/GGT twice the ULN were classified as mixed type (Abnormality type (1)). To further describe liver test characteristics, we defined ALT and/or AST over $3\times$ ULN, ALP, GGT, and/or TBIL over $2\times$ ULN as liver injury. Moreover, as the magnitude of the liver test elevations in our patients ranged from mild to moderate, we also defined patterns of liver abnormality according to another criteria. Patients were classified as hepatocyte type when the AST/ALT activity was higher than the ALP/GGT activity, with the liver enzyme activities calculated by multiples of their ULN, respectively, and were classified as cholangiocyte type when the reverse occurred (Abnormality type (2)).

Severity of COVID-19

As per the national guidelines for community-acquired pneumonia and the diagnosis and treatment plan for the new coronavirus in China,^{18,19} all patients were classified into severe or mild cases based on results from chest radiography, clinical examination, and symptoms. Patients with mild symptoms (*i.e.*, fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types.⁸ A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura. Severe pneumonia was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR ≥ 30 times/minute; ii) hypoxia: oxygen saturation (resting state) $\leq 93\%$; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO_2 / FiO_2) ≤ 300 mmHg (millimeters of Mercury); or iv) the occurrence of respiratory or other organ failure that requires intensive care unit (ICU) monitoring and treatment, or shock.

We also investigated the pathological characteristics of a patient who died from COVID-19 by obtaining biopsy samples at autopsy.

Statistical analysis

Categorical variables were described as frequency and percentages, and continuous variables as mean and SD or median and IQR. Means for continuous variables were compared using independent group *t* tests when the data were normally distributed; otherwise, the Mann-Whitney *U* test was used. Comparison of categorical variables was done using the χ^2 test or the Fisher exact test, if the cell counts were small. Multivariable logistic regression was used to explore the association between liver test abnormalities and the severity of disease, and the association between drugs and liver injury, using odds ratios (ORs) and 95% CIs. As the presence of underlying liver disease may also play a role in the association of liver tests with disease severity, we also conducted sensitivity analyses excluding patients with underlying liver disease, including chronic hepatitis B and alcoholic/non-alcoholic fatty liver disease (NAFLD). NAFLD was defined by ultrasonographic detection or CT measurements of steatosis, with the exclusion of both secondary causes and of a daily alcohol consumption ≥ 30 gram in men and ≥ 20 gram in

women.²⁰ HBV infection was defined by the positive test for hepatitis B surface antigen.²¹ Furthermore, we used inverse probability weighting (IPW) to adjust for potential confounders and to account for possible selection bias induced by the severity of disease at admission when examining the effects of drugs on liver injury. All statistical analyses were performed using STATA/SE version 16.0 software (StataCorp. 2019. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC). A 2-sided α of less than 0.05 was considered statistically significant.

Results

Clinical features of patients with COVID-19

Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. Ninety-one (21.8%) developed severe disease and 326 (78.2%) had mild disease during hospitalization (Fig. 1).

Clinical features of patients with COVID-19 at admission

Table 1 shows that at admission, about half of the patients had abnormal liver test results and 21 (5%) had liver injury. Patients with abnormal liver test results were older, had a higher body mass index (BMI), were male, and had no clear contact history ($p < 0.05$). Patients also tended to have underlying liver diseases, including NAFLD, alcoholic liver disease, and chronic hepatitis B ($p = 0.001$), and had cough as an initial symptom ($p = 0.04$) (Table 1). Most of the patients had abnormal liver test results within 1–2 \times ULN at admission and only a few (<4%) had abnormal liver test results higher than 2 \times ULN. The increase in GGT at admission appeared to be more pronounced, with 53 (12.71%) having 1–2 \times ULN, 5 (1.2%) having 2–3 \times ULN, and 10 (2.4%) having more than 3 \times ULN (Table 1).

Clinical features of patients with COVID-19 and abnormal liver tests during hospitalization

Table 2 shows that, of the 318 patients with COVID-19 and abnormal liver test results during hospitalization, 26.7% progressed to severe pneumonia. Regarding the patterns of abnormal liver test results, 20.75% were hepatocyte type, 29.25% were cholestatic type, and 43.4% were mixed type (Table 2). The presence of liver test abnormalities became more pronounced during hospitalization for ALT, AST, TBIL and GGT, with 33 (10.38%), 18 (5.66%), 9 (2.83%), and 37 (11.64%) patients exhibiting abnormal levels more than 3 \times ULN, respectively (Table 2).

Table 2 also shows that, in the 318 patients with abnormal liver test results, those who progressed to severe cases tended to be mixed type ($p = 0.01$), had higher ALT, AST, TBIL and GGT ($p < 0.005$), but not ALP (Table 2). The use of drugs that may induce liver injury including antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), ribavirin, herbal medications, and interferon were associated with severity of disease (all $p \leq 0.001$) in patients with abnormal liver test results, except for lopinavir/ritonavir ($p = 0.66$) and oseltamivir ($p = 0.14$).

Clinical features of patients with COVID-19 and liver injury during hospitalization

Table 3 shows that in 90 patients with COVID-19 and liver injury during hospitalization, about half were severe cases. Increases in ALT and GGT were frequent (elevated to more than 3 \times ULN in 37% and 41% of patients, respectively), while increases in AST and TBIL were slightly less frequent (elevated to more than 3 \times ULN in 20% and 10% of patients, respectively). The increase in ALP was not pronounced, with only 1 patient exhibiting an elevation to more than 3 \times ULN. The use of antibiotics, NSAIDs, Chinese herbal medications, and interferon were associated with progression to severe disease (p from <0.001 to 0.04). Moreover, 10 (23.26%) of the severe cases presented with multi-organ failure. Of the 10 patients who developed multiple organ failure, 3 patients died (1 patient had liver failure). In addition to respiratory failure, these 10 patients had other complications, including liver failure (2/10), septic shock (9/10), heart failure (4/10), renal failure (8/10), gastrointestinal hemorrhage (1/10), and disseminated intravascular coagulation (2/10). Except for respiratory failure, most of these complications, including liver failure, were related to severe secondary infections in the ICU.

Association of abnormal liver function tests and COVID-19 disease severity by multivariate analysis

Table 4 shows that, after adjustment for age, sex, epidemiological history, liver comorbidities, and initial symptoms, abnormality or injury as indicated by liver tests at admission was not associated with disease severity. Using the definition of abnormality type (1), patients with hepatocellular type were at almost 3-fold greater risk of severe COVID-19 compared to those without liver test abnormalities (OR 2.73; CI 1.19–6.30; $p = 0.02$) and those with a mixed abnormality were at 4.44 higher odds of severe disease (OR 4.44; CI 1.93–10.23; $p < 0.001$). Moreover, when using the definition of abnormality type (2), patients who were classified as hepatocellular type and cholestatic type were at ~3-fold greater risk of developing severe COVID-19 (OR 3.83; 95% CI 1.45–10.11; $p = 0.007$ and OR 3.45; 95% CI 1.25–9.5; $p = 0.02$, respectively). Sensitivity analyses excluding 21 patients with preexisting liver disease showed similar results, with the adjusted ORs (95% CIs) for severity being 1.73 (0.94–3.16) and 1.86 (0.58–5.92) in patients with abnormal liver tests and liver injury, respectively (Table not shown).

After similar adjustment, patients with liver injury were at a 9-fold greater risk of severe COVID-19 (OR 9.04; 95% CI 3.19–25.6; $p < 0.001$). Having hepatocyte type or a mixed type (OR 3.19; 95% CI 1.15–8.84, and 11.22; 95% CI 4.42–28.45, respectively) also increased the odds of developing severe disease. Sensitivity analyses excluding 21 patients with preexisting liver disease showed similar results, with the adjusted ORs (95% CIs) for severity being 2.41 (0.91–6.42) and 9.62 (3.34–27.7) in




Fig. 1. Liver test abnormality during hospitalization in patients with COVID-19 by severity of disease. (Bars represent number of patients).

Table 1. Characteristics of 417 patients with COVID-19 at admission by liver tests.

Characteristics	Liver tests			Total	p value
	Normal	Abnormal	Injury		
Number (%)	225 (54.0)	170 (41.0)	22 (5.0)	417	
Age, year, median (IQR)	47 (33–59)	47 (33–61)	53 (42–64)	47 (34–60)	0.04
<10	5 (2.22)	15 (8.77)	0 (0)	20 (4.8)	0.03
10–19	7 (3.11)	7 (4.09)	0 (0)	14 (3.36)	
20–39	75 (33.33)	50 (29.24)	3 (14.29)	128 (30.7)	
40–49	39 (17.33)	20 (11.7)	5 (23.81)	64 (15.35)	
≥50	99 (44)	79 (46.2)	13 (61.9)	191 (45.8)	
Males, n (%)	81 (36)	103 (60.2)	14 (66.7)	198 (47.5)	<0.001
BMI, kg/m ² , median (IQR)	22.6 (20.6–25)	23.7 (21.4–26.2)	25.8 (22.2–27)	23.1 (21.2–25.6)	0.004
Epidemiology information, n (%)					
From Hubei	135 (60)	82 (47.95)	9 (42.86)	226 (54.2)	0.03
Not been to Hubei, but infected by individuals from Hubei	80 (35.56)	70 (40.94)	9 (42.86)	159 (38.13)	
Without any clear contact history	10 (4.44)	19 (11.11)	3 (14.29)	32 (7.67)	
Comorbidities, n (%)					
Diabetes	12 (5.33)	10 (5.85)	1 (4.76)	23 (5.52)	0.96
Hypertension	25 (11.11)	27 (15.79)	6 (28.57)	58 (13.91)	0.06
Liver disease [†]	4 (1.78)	14 (8.19)	3 (14.29)	21 (5.04)	0.001
Initial symptoms, n (%)					
Fever	147 (65.3)	118 (69.0)	14 (66.7)	279 (66.9)	0.74
Cough	73 (32.4)	73 (42.7)	11 (52.4)	157 (37.7)	0.04
Chest radiography, n (%)					
No Change	29 (12.89)	35 (20.47)	2 (9.52)	66 (15.83)	0.18
Mild	36 (16)	20 (11.7)	1 (4.76)	57 (13.67)	
Advanced	140 (62.2)	96 (56.14)	15 (71.4)	251 (60.2)	
Severe	20 (8.89)	20 (11.7)	3 (14.29)	43 (10.31)	
ALT, U/L, median (IQR)	17 (12–24)	27 (18–39.5)	47 (38–65.2)	21 (15–31)	<0.001
Normal	225 (100)	132 (77.19)	6 (28.57)	363 (87.1)	<0.001
1–2 ULN, n (%)	0 (0)	35 (20.47)	13 (61.9)	48 (11.51)	
2–3 ULN, n (%)	0 (0)	4 (2.34)	1 (4.76)	5 (1.2)	
>3 ULN, n (%)	0 (0)	0 (0)	1 (4.76)	1 (0.24)	
AST, U/L, median (IQR)	23 (19–28)	34 (24.3–43)	47.2 (30.9–63.8)	26.5 (21–35)	<0.001
Normal	225 (100)	108 (63.16)	8 (38.1)	341 (81.77)	<0.001
1–2 ULN, n (%)	0 (0)	58 (33.92)	11 (52.38)	69 (16.55)	
2–3 ULN, n (%)	0 (0)	5 (2.92)	1 (4.76)	6 (1.44)	
>3 ULN, n (%)	0 (0)	0 (0)	1 (4.76)	1 (0.24)	
TBIL, μmol/L, median (IQR)	9.55 (7.6–12.6)	16.8 (9.3–22)	17.2 (9.2–34.3)	10.9 (8.3–16.3)	<0.001
Normal	222 (100)	86 (50.29)	10 (47.62)	318 (76.81)	<0.001
1–2 ULN, n (%)	0 (0)	85 (49.71)	5 (23.81)	90 (21.74)	
2–3 ULN, n (%)	0 (0)	0 (0)	5 (23.81)	5 (1.21)	
>3 ULN, n (%)	0 (0)	0 (0)	1 (4.76)	1 (0.24)	
ALP, U/L, median (IQR)	59 (48–70.5)	63 (52–79)	68 (56–81)	61 (50.5–74.5)	<0.001
Normal	180 (100)	120 (88.89)	16 (94.12)	316 (95.18)	<0.001
1–2 ULN, n (%)	0 (0)	14 (10.37)	1 (5.88)	15 (4.52)	
2–3 ULN, n (%)	0 (0)	1 (0.74)	0 (0)	1 (0.3)	
>3 ULN, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	
GGT, U/L, median (IQR)	21.71 (9.04)	36.45 (21.94)	134.91 (108.04)	33.45 (37.41)	<0.001
Normal	225 (100)	120 (70.18)	4 (19.05)	349 (83.69)	<0.001
1–2 ULN, n (%)	0 (0)	51 (29.82)	2 (9.52)	53 (12.71)	
2–3 ULN, n (%)	0 (0)	0 (0)	5 (23.81)	5 (1.2)	
>3 ULN, n (%)	0 (0)	0 (0)	10 (47.62)	10 (2.4)	

ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; NSAIDs, non-steroidal anti-inflammatory drugs; TBIL, total bilirubin abnormal; ULN, upper limit of normal.

[†]Liver comorbidities include non-alcoholic fatty liver disease, alcoholic liver disease and chronic hepatitis B.

patients with abnormal liver tests and liver injury during hospitalization, respectively (Table not shown).

Moreover, after similar adjustment, patients treated with ACE-inhibitors/angiotensin II receptor blockers (ARBs) did not show differential odds for severe disease compared to patients taking other antihypertensive drugs (*i.e.*, nifedipine), with the adjusted OR being 0.70 (95% CI 0.20–2.36; *p* = 0.56) (Table not shown).

Compared to those without the use of the suspected drugs that may lead to liver dysfunction (including antibiotics, NSAIDs,

ribavirin, herbal medications, and interferon), no significant evidence showed the use of such drugs led to a higher risk of liver injury (*p* > 0.05 in IPW estimation), except for lopinavir/ritonavir (OR 4.44; 95% CI 1.50–13.17 in multivariable model and 5.03, 1.78–14.23 in the IPW estimation; *p* < 0.01) (Fig. 2). Patients who used lopinavir/ritonavir had much higher levels of TBIL and GGT during hospitalization (*p* from <0.004) (Table S1). One patient aged 69 years who died from COVID-19 had a liver biopsy. Histological examination showed no obvious inflammation in the portal area (Fig. 3A). The structure of the interlobular bile duct,

Table 2. Clinical characteristics of 318 patients with COVID-19 and abnormal liver test results during hospitalization.

Characteristics	Disease severity		Total	p value
	Non-severe	Severe		
N (%)	233 (73.27)	85 (26.73)	318	–
Abnormality type, n (%)				
Hepatocellular	50 (21.46)	16 (18.82)	66 (20.75)	<0.001
Cholestatic	86 (36.91)	7 (8.24)	93 (29.25)	
Mixed	78 (33.48)	60 (70.59)	138 (43.4)	
ALT, U/L, Median (IQR)	41 (23–65)	67 (47–100)	46 (27–76)	0.003
Normal	116 (49.79)	15 (17.65)	131 (41.19)	<0.001
1–2 ULN, n (%)	75 (32.19)	38 (44.71)	113 (35.53)	
2–3 ULN, n (%)	27 (11.59)	14 (16.47)	41 (12.89)	
>3 ULN, n (%)	15 (6.44)	18 (21.18)	33 (10.38)	
AST, U/L, Median (IQR)	34 (27–45)	58 (41–93)	38 (28–52)	0.005
Normal	147 (63.09)	21 (24.71)	168 (52.83)	<0.001
1–2 ULN, n (%)	74 (31.76)	39 (45.88)	113 (35.53)	
2–3 ULN, n (%)	10 (4.29)	9 (10.59)	19 (5.97)	
>3 ULN, n (%)	2 (0.86)	16 (18.82)	18 (5.66)	
TBIL, μ mol/L, Median (IQR)	19 (13–26)	22 (18–28)	20 (14–27)	<0.001
Normal	93 (39.91)	21 (24.71)	114 (35.85)	<0.001
1–2 ULN, n (%)	123 (52.79)	58 (68.24)	181 (56.92)	
2–3 ULN, n (%)	14 (6.01)	0 (0)	14 (4.4)	
>3 ULN, n (%)	3 (1.29)	6 (7.06)	9 (2.83)	
ALP, U/L, Median (IQR)	69 (57–89)	79 (62–101)	73 (59–92)	0.31
Normal	180 (89.55)	72 (87.8)	252 (89.05)	0.78
1–2 ULN, n (%)	20 (9.95)	9 (10.98)	29 (10.25)	
2–3 ULN, n (%)	1 (0.5)	1 (1.22)	2 (0.71)	
>3 ULN, n (%)	0 (0)	0 (0)	0 (0)	
GGT, U/L, Median (IQR)	40 (25–61)	92 (53–161)	47.5 (28–83)	<0.001
Normal	142 (60.94)	21 (24.71)	163 (51.26)	<0.001
1–2 ULN, n (%)	67 (28.76)	25 (29.41)	92 (28.93)	
2–3 ULN, n (%)	12 (5.15)	14 (16.47)	26 (8.18)	
>3 ULN, n (%)	12 (5.15)	25 (29.41)	37 (11.64)	
Drug-use, n (%)				
Antibiotics	14 (29.79)	33 (76.74)	47 (52.22)	<0.001
NSAIDs	78 (33.48)	57 (67.06)	135 (42.45)	<0.001
Ribavirin	57 (24.46)	38 (44.71)	95 (29.87)	<0.001
Oseltamivir	55 (23.61)	27 (31.76)	82 (25.79)	0.14
Herbal medications	189 (81.12)	83 (97.65)	272 (85.53)	<0.001
Interferon	196 (84.12)	83 (97.65)	279 (87.74)	0.001
Lopinavir/ritonavir	210 (90.13)	78 (91.76)	288 (90.57)	0.66
Multi-organ failure, n (%)	0 (0)	10 (11.76)	10 (3.14)	–
Liver failure	0	2	2	

ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; NSAIDs, non-steroidal anti-inflammatory drugs; TBIL, total bilirubin abnormal; ULN, upper limit of normal.

interlobular vein, and interlobular artery were clear; the hepatocytes in the interlobular region were orderly, and a few hepatocytes were observed to have slightly vesicular steatosis and watery degeneration (probably due to ischemia and hypoxia). In Fig. 3B, slight vesicular steatosis and watery degeneration were observed in the hepatocytes, and a few inflammatory cells (neutrophils, plasma cells, and Kupffer cells) were found in the hepatic sinuses.

Discussion

Our study is the first, and perhaps most comprehensive, to describe the liver test results in patients with COVID-19. Compared to patients with normal liver tests at admission, those who had abnormal liver test results, especially in hepatocyte type or mixed type, had significantly higher risks of developing severe pneumonia. As almost all patients had liver tests at admission, liver test abnormalities can be used as a predictor for the severity of the disease. More than 90% of patients with abnormal liver tests were mild at admission (i.e., with <2 \times ULN), and about 24% of them developed increased ALT and GGT levels

to substantially more than 3 \times ULN during hospitalization. However, the increase in AST and TBIL to more than 3 \times ULN were moderate (12% and 15%, respectively), and no increase in ALP was found. Patients with elevated liver enzymes classified as hepatocyte type at admission or during hospitalization had significantly higher odds of progressing to severe COVID-19. After admission, the use of drugs, especially lopinavir and ritonavir, was the most important risk factor for liver damage. The use of lopinavir/ritonavir increased the odds of liver injury by 4-fold. Thus, it is suggested to closely monitor patients who used these particular therapies, especially in those who had abnormal liver test results at admission.

The liver test abnormality rate in our study was higher than previously reported and only a small portion had underlying liver disease, suggesting that liver damage in patients with coronavirus infection might be directly caused by the viral infection of liver cells.²² Two recent studies showed that ACE2 was the key receptor for SARS-CoV-2 cell entry,^{23,24} which was mainly localized in the heart, kidney, and testes, and expressed at a low level in many other tissues, especially in the colon and

Table 3. Clinical characteristics of patients with COVID-19 and liver injury.

Characteristics	Disease severity		Total	p value
	Non-severe	Severe		
N (%)	47 (52.22)	43 (47.78)	90	–
Abnormality type (1), [†] n (%)				
Hepatocellular	8 (17.02)	0 (0)	8 (8.89)	0.001
Cholestatic	8 (17.02)	2 (4.65)	10 (11.11)	
Mixed	28 (59.57)	41 (95.35)	69 (76.67)	
Abnormality type (2), [†] n (%)				
Hepatocellular	20 (42.55)	17 (39.53)	37 (41.11)	0.77
Cholestatic	27 (57.45)	26 (60.47)	53 (58.89)	
ALT, U/L, Median (IQR)	84 (42–136)	96 (63–159)	90.5 (53–145)	0.17
Normal	10 (21.28)	2 (4.65)	12 (13.33)	0.14
1–2 ULN, n (%)	12 (25.53)	13 (30.23)	25 (27.78)	
2–3 ULN, n (%)	10 (21.28)	10 (23.26)	20 (22.22)	
>3 ULN, n (%)	15 (31.91)	18 (41.86)	33 (36.67)	
AST, U/L, Median (IQR)	45 (29–81)	80 (56–145)	63 (36–101)	0.1
Normal	20 (42.55)	4 (9.3)	24 (26.67)	<0.001
1–2 ULN, n (%)	15 (31.91)	16 (37.21)	31 (34.44)	
2–3 ULN, n (%)	10 (21.28)	7 (16.28)	17 (18.89)	
>3 ULN, n (%)	2 (4.26)	16 (37.21)	18 (20)	
TBIL, μ mol/L, Median (IQR)	22 (15–41)	25 (19–32)	23.5 (16–37)	0.13
Normal	16 (34.04)	9 (20.93)	25 (27.78)	<0.001
1–2 ULN, n (%)	14 (29.79)	28 (65.12)	42 (46.67)	
2–3 ULN, n (%)	14 (29.79)	0 (0)	14 (15.56)	
>3 ULN, n (%)	3 (6.38)	6 (13.95)	9 (10)	
ALP, U/L, Median (IQR)	77 (65–97)	92 (76–130)	83 (66–114.5)	0.01
Normal	39 (95.12)	33 (76.74)	72 (85.71)	0.05
1–2 ULN, n (%)	2 (4.88)	9 (20.93)	11 (13.1)	
2–3 ULN, n (%)	0 (0)	1 (2.33)	1 (1.19)	
>3 ULN, n (%)	0 (0)	0 (0)	0 (0)	
GGT, U/L, Median (IQR)	101 (39–148)	161 (122–211)	130.5 (77–187)	<0.001
Normal	16 (34.04)	0 (0)	16 (17.78)	<0.001
1–2 ULN, n (%)	7 (14.89)	4 (9.3)	11 (12.22)	
2–3 ULN, n (%)	12 (25.53)	14 (32.56)	26 (28.89)	
>3 ULN, n (%)	12 (25.53)	25 (58.14)	37 (41.11)	
Drug-use, n (%)				
Antibiotics	14 (29.79)	33 (76.74)	47 (52.22)	<0.001
NSAIDs	18 (38.3)	29 (67.44)	47 (52.22)	
Ribavirin	16 (34.04)	17 (39.53)	33 (36.67)	0.59
Oseltamivir	11 (23.4)	17 (39.53)	28 (31.11)	0.10
Herbal	42 (89.36)	43 (100)	85 (94.44)	0.03
Interferon	38 (80.85)	41 (95.35)	79 (87.78)	0.04
Lopinavir/ritonavir	45 (95.74)	41 (95.35)	86 (95.56)	0.93
Multi-organ failure, n (%)	0 (0)	10 (23.26)	10 (11.11)	–

ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; NSAIDs, non-steroidal anti-inflammatory drugs; TBIL, total bilirubin abnormal; ULN, upper limit of normal.

[†]Abnormality type (1): Patients who had raised ALT and/or AST more than 3× the ULN were classified as hepatocyte type; patients who had raised ALP or GGT twice the ULN were classified as cholangiocytes type; and patients who had a raised combination of both ALT/AST more 3 time the ULN and ALP/GGT twice the ULN were classified as mixed type. Abnormality type (2): patients were classified as hepatocyte type when the AST/ALT activity was higher than the ALP/GGT activity and were classified as cholangiocyte type when the reverse occurred.

lung.²⁵ Another recent study showed that SARS-CoV-2 might directly bind to ACE2 positive cholangiocytes and cause liver damage,⁷ which may partially explain the contribution of SARS-CoV-2 infection to the liver test dysfunction in our patients. Moreover, the use of ACE-inhibitors and ARBs might also affect liver tests. All patients in this study with hypertension used ACE-inhibitors/ARBs at admission, subsequently, these medications may have influenced their abnormal liver tests. However, although we found that those receiving ACE-inhibitors/ARBs appeared to have a higher percentage of abnormal liver tests at admission (15.6–28.6% vs. 11.1%), the difference was not statistically significant. Additionally, we excluded these 58 patients with hypertension at admission and found that the prevalence of abnormal liver function tests remained similar (from 46% to

44%), suggesting that the influence of ACE-Is/ARBs drugs on liver tests at admission, if any, should be minor. Moreover, our study showed that patients treated with ACE-inhibitors/ARBs were not at increased odds of progressing to severe disease compared to patients taking other antihypertensive drugs. The prevalence of abnormal liver tests increased to 76% during hospitalization, which could be due to a more frequent examination (*i.e.*, every 3 to 5 days) and drugs used during hospitalization. Note that 84% of patients used lopinavir/ritonavir during hospitalization, drugs which have been reported to cause liver damage and affect liver tests.²⁶

In our study, GGT was elevated substantially at admission and increased to a much higher level during hospitalization, whereas the increase in ALP was not pronounced. Both GGT and ALP were

Table 4. Association of abnormal liver test results with COVID-19 severity (severe vs. non-severe).

	Crude OR (95% CIs)	p value	Adjusted OR (95% CIs) [†]	p value
At admission				
Liver tests				
Normal	1.00		1.00	
Abnormal	1.93 (1.18–3.16)	0.009	1.64 (0.91–2.95)	0.10
Injury	3.94 (1.55–10.03)	0.004	2.03 (0.69–5.98)	0.20
Abnormality type (1) [‡]				
Normal	1.00		1.00	
Hepatocellular	5.26 (2.58–10.75)	<0.001	2.73 (1.19–6.3)	0.02
Cholestatic	1.07 (0.54–2.13)	0.84	1.28 (0.58–2.82)	0.55
Mixed	4.82 (2.42–9.6)	<0.001	4.44 (1.93–10.23)	<0.001
Abnormality type (2) [‡]				
Normal	1.00		1.00	
Hepatocellular	2.34 (1.36–4.03)	0.002	1.64 (0.86–3.12)	0.14
Cholestatic	1.83 (1.00–3.35)	0.049	1.75 (0.84–3.64)	0.14
Peak values of liver test parameters during hospitalization				
Liver tests				
Normal	1.00		1.00	
Abnormal	3.5 (1.44–8.53)	0.006	2.48 (0.94–6.55)	0.07
Injury	14.18 (5.63–35.7)	<0.001	9.04 (3.19–25.6)	<0.001
Abnormality type (1) [‡]				
Normal	1.00		1.00	
Hepatocellular	4.48 (1.8–11.15)	0.001	3.19 (1.15–8.84)	0.03
Cholestatic	1.14 (0.4–3.26)	0.81	1.09 (0.34–3.49)	0.88
Mixed	10.77 (4.88–23.78)	<0.001	11.22 (4.42–28.45)	<0.001
Abnormality type (2) [‡]				
Normal	1.00		1.00	
Hepatocellular	6.05 (2.49–14.71)	<0.001	3.83 (1.45–10.11)	0.007
Cholestatic	5.17 (2.08–12.83)	<0.001	3.45 (1.25–9.5)	0.02

ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; OR, odds ratio; ULN, upper limit of normal.

[†]Adjusted for age, sex, epidemiological history, body mass index, liver comorbidity and cough.

[‡]Abnormality type (1): Patients who had raised ALT and/or AST more than 3× the ULN were classified as hepatocyte type; patients who had raised ALP or GGT twice the ULN were classified as cholangiocytes type; and patients who had a raised combination of both ALT/AST more 3 time the ULN and ALP/GGT twice the ULN were classified as mixed type. Abnormality type (2): patients were classified as hepatocyte type when the AST/ALT activity was higher than the ALP/GGT activity, and were classified as cholangiocyte type when the reverse occurred.




Fig. 2. Adjusted odds ratios (95% CIs) for liver injury associated with use of drugs in patients with COVID-19. All results were adjusted for radiography image grade at admission, age, sex, body mass index and comorbidities. Triangle legends for results from multivariable regression and circle legends for inverse probability weighting. Levels of significance: both *p* values <0.01 for lopinavir/ritonavir; all *p* values >0.05 for other drugs (multivariable logistic regression). IPW, inverse probability weighting; NSAIDs, non-steroidal anti-inflammatory drugs.

considered as “cholangiocyte-related enzymes”. However, besides the bile duct, ALP is present in bone, intestine, kidney, and placenta, while GGT is mainly distributed in the cell membranes of many tissues including kidneys, bile duct, pancreas, gall-bladder, spleen, heart, brain, and seminal vesicles. Hence, for bile duct injury, ALP is more sensitive than GGT. For patients with elevated GGT level and normal ALP, drug-induced liver injury and injury in other organs should be considered, but cannot be classified into the bile duct type.^{27,28}

We observed a substantial increase in the incidence of liver injury after admission. In our study, about 90% patients with abnormal liver test results were mild at admission (i.e., with <2× ULN), and more than 10% of them had increased levels of ALT and GGT (more than 3× ULN) during hospitalization. The increases in AST and TBIL to more than 3× ULN were moderate (about 6% and 3%, respectively), and no increase in ALP was found. For these patients, there were few other factors affecting liver test abnormality, such as underlying liver disease and drug usage, hence, we speculate that the disease itself is the most likely cause of this change. However, for hospitalized patients, more attention should be paid to drug-induced liver damage.

In addition, the liver biopsy specimens of the patient who died from COVID-19 showed that the raised liver enzymes during hospitalization could be partly due to the drugs used for treatment, and the observed liver test abnormality might be due to sepsis and shock. The 2 cases of liver failure occurring in patients with sepsis and multiple organ failure also support this hypothesis.




Fig. 3. Liver biopsy of 1 patient aged 69 years who died from the COVID-19. (A) (20×) There was no obvious inflammation in the portal area. The structure of interlobular bile duct, interlobular vein and interlobular artery was clear; the hepatocytes in the interlobular were arranged orderly, and a few hepatocytes were observed slightly vesicular steatosis and watery degeneration (possibly related to ischemia and hypoxia). (B) (40×) The hepatocytes were observed slightly vesicular steatosis and watery degeneration, and a few inflammatory cells (neutrophils, plasma cells and Kupffer cells) were found in hepatic sinuses.

As it may take years to develop new agents specifically for SARS-CoV-2, an efficient approach is to test whether existing antiviral drugs are effective in treating the SARS-CoV-2 infection. Our study showed that the use of lopinavir/ritonavir was associated with 4× higher odds of liver injury. Lopinavir/ritonavir have previously been used to treat patients with SARS²³ and HIV²⁴ infections in China and are widely used (84%) in our patients with COVID-19. However, given the potentially high risk of liver injury, efficacy and safety of these therapies warrant further investigation. Moreover, in China, drug-induced liver impairment is most frequently reported with antibiotics and Chinese herbal medicine.²⁹ The present study suggested that the use of antibiotics, but not Chinese herbal medicine, was associated with liver injury in patients with SARS-CoV-2 infection in the multi-variable regression model. Although the results from the IPW model did not show statistical significance, it is also important for clinicians to be aware of these cases, which may need to be carefully monitored.

Compared to patients with normal liver tests, those who had abnormal liver test results, especially in hepatocyte or mixed type (i.e., raised ALT/AST, or both ALT/AST and ALP/GGT) at admission or during hospitalization had significantly higher odds of progressing to severe COVID-19. Exacerbation to severe pneumonia is an important clinical endpoint, indicating a higher mortality rate, requiring ICU support, or mechanical ventilation. In previous studies, the risk factors of severe COVID-19 included age, gender, and underlying diseases.^{8,9,30–32} This is one of the first reports to highlight abnormal liver tests related to severe disease. It is speculated that the SARS-CoV-2 virus is not only highly transmissible, but may also cause severe multi-organ dysfunction in humans,^{33,34} and our results, to some extent, support this hypothesis.

The present study has some limitations. First, as patients of this study were from a single, large city in China, these findings cannot be generalized to rural communities or other regions of varying epidemiological characteristics. Second, as very few patients died from the disease in our study (only 3 patients died during the course of the study), the potential influence of liver abnormality or injury on mortality cannot be assessed. As new cases are emerging globally, further studies in large patient series are warranted. In addition, data on other causes of liver injury in the patients progressing to liver injury, such as herbal medicines or other drugs used as self-medication before

developing COVID-19 pneumonia, were not available from our patients. However, since the start of the COVID-19 outbreak in China in December 2019, discussion about COVID-19 has spread rapidly on the Internet and has quickly become the focus of worldwide attention. Shenzhen is one of the most developed cities in China and access to the Internet is widespread, meaning many in the population would have a high degree of awareness of the disease. Most (i.e., >70%) patients went to the hospital within 5 days after the onset disease symptoms and rarely used over-the-counter medicine to self-treat because medical insurance is widely available in Shenzhen. Hence, although the data on herbs and other drugs used as self-medication before developing COVID-19 pneumonia was not available in our study, their influence on the results might not be substantial. Lastly, we did not apply the definition of drug-induced liver injury from the European Association for the Study of the Liver clinical practice guidelines,³⁵ as currently there was no evidence indicating that the abnormal liver injury during hospitalization was fully induced by the drugs used.

In conclusion, we estimated the clinical characteristics of COVID-19 pneumonia in patients with abnormal liver test results. Patients with abnormal liver tests were at increased risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, and should be monitored and evaluated frequently.

Abbreviations

ACE, angiotensin-converting enzyme; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARBs, angiotensin II receptor blockers; AST, aspartate aminotransferase; BMI, body mass index; COVID-19, coronavirus disease 2019; GGT, gamma-glutamyltransferase; ICU, intensive care unit; IPW, inverse probability weighting; NAFLD, non-alcoholic fatty liver disease; NSAID, non-steroidal anti-inflammatory drugs; OR, odds ratio; SARS-CoV2, severe acute respiratory syndrome coronavirus 2; TBIL, total bilirubin; ULN, upper limit unit of normal; WHO, World Health Organization.

Financial support

This work is supported by the National Clinical Research Center for Infectious Diseases, Funds for the construction of key medical disciplines in Shenzhen and the Sanming Project of Medicine in Shenzhen (SZSM201612014).

Conflict of interest

The authors declare no conflicts of interest that pertain to this work.

Please refer to the accompanying [ICMJE disclosure](#) forms for further details.

Authors' contributions

JC and LL had the idea for and designed the study, received the grant supports and had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. QC, DH, HY and XL contributed to the writing of the report. LX, HY, ZZ and QH contributed to the critical revision of the report. QC, and XL contributed to the statistical analysis. All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version.

Acknowledgements

We thank Sarah Robbins Scott, an independent consultant for her help in English writing.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2020.04.006>.

References

Author names in bold designate shared co-first authorship

- [1] Dong Y, Liang X, Yu X. Prognostic value of the dynamic changes in extra vascular lung water index and angiotensin-2 in severe multiple trauma patients with acute respiratory distress syndrome. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2019;31:571–576.
- [2] Niu P, Shen J, Zhu N, Lu R, Tan W. Two-tube multiplex real-time reverse transcription PCR to detect six human coronaviruses. *Virologica Sinica* 2016;31:85–88.
- [3] **Lu R, Zhao X, Li J**, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;395:565–574.
- [4] Jia Z, Yan L, Ren Z, Wu L, Tsang TY, Guo J, et al. Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis. *Nucleic Acids Res* 2019;47:6538–6550.
- [5] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.2648>. Published online February 24, 2020.
- [6] Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. *Hepatology* 2004;39:302–310.
- [7] Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. *bioRxiv* 2020. <https://doi.org/10.1101/2020.02.03.931766>.
- [8] **Chen N, Zhou M, Dong X, Qu J**, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395:507–513.
- [9] **Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y**, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.
- [10] **Tian S, Hu N, Lou J, Chen K**, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. *J Infect* 2020;80:401–406.
- [11] **Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX**, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMoa2002032>. Published online February 28, 2020.
- [12] **Yang W, Cao Q, Qin L, Wang X**, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. *J Infect* 2020;80:388–393.
- [13] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020. <https://doi.org/10.1111/all.14238>. Published online 19 February 2020.
- [14] **Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J**, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061–1069.
- [15] **Xu Z, Shi L, Wang Y**, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020. [https://doi.org/10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X). Published online February 18, 2020.
- [16] World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. Available at, 2020. [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected). [Accessed 31 January 2020].
- [17] **Bai Y, Yao L, Wei T**, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier transmission of COVID-19. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.2565>. Published online February 21, 2020.
- [18] **Metlay JP, Waterer GW**, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of Adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019;200:e45–e67.
- [19] National Health Commission of the People's Republic of China. Handbook of Prevention and Treatment of the Pneumonia Caused by the Novel Coronavirus (2019-nCoV) (in Chinese). Updated: February 6, 2020. Available at: 2020. http://en.nhc.gov.cn/2020-02/06/c_76295.htm. [Accessed 23 February 2020].
- [20] European Association for the Study of the Liver, European Association for the Study of Diabetes. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *Obes Facts* 2016;9:65–90.
- [21] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017;67:370–398.
- [22] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020. [https://doi.org/10.1016/S2468-1253\(20\)30057-1](https://doi.org/10.1016/S2468-1253(20)30057-1). Published online March 04, 2020.
- [23] **Hoffmann M, Kleine-Weber H**, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020. <https://doi.org/10.1016/j.cell.2020.02.052>. Published online March 05, 2020.
- [24] **Yan R, Zhang Y**, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 2020;367:1444–1448.
- [25] Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. *Int J Hypertens* 2012;2012:307315.
- [26] Meraviglia P, Schiavini M, Castagna A, Viganò P, Bini T, Landonio S, et al. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. *HIV Med* 2004;5:334–343.
- [27] Dillon JF, Miller MH. Gamma glutamyl transferase 'To be or not to be' a liver function test? London, England: SAGE Publications Sage UK; 2016.
- [28] Fernandez NJ, Kidney BA. Alkaline phosphatase: beyond the liver. *Vet Clin Pathol* 2007;36:223–233.
- [29] **Zhu Y, Niu M**, Chen J, Zou Z-s, Ma Z-j, Liu S-h, et al. Hepatobiliary and pancreatic: comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. *J Gastroenterol Hepatol* 2016;31:1476–1482.
- [30] **Wang D, Hu B**, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020.
- [31] **Xu XW, Wu XX**, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020;368:m606.
- [32] **Zhu N, Zhang D, Wang W, Li X**, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020;382:727–733.
- [33] MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.2342>. Published online February 19, 2020.
- [34] Zhang W. Imaging changes of severe COVID-19 pneumonia in advanced stage. *Intensive Care Med* 2020;1–3.
- [35] Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Karlsen TH, et al. EASL clinical practice guidelines: drug-induced liver injury. *J Hepatol* 2019;70:1222–1261.